Phase 4 N=42 Randomized Quadruple-blind Treatment

The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation

Nasal Obstruction

Bottom Line

View on ClinicalTrials.gov: NCT02877485 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2020

Primary outcome: Primary: Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline Spray) — 69.1; 68.5; 65.2; 65.8 score on a scale — p=0.7

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Triamcinolone Acetonide (Drug); Ayr saline nasal mist (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Stanford University
Primary completion: Aug 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline Spray)	69.1; 68.5; 65.2; 65.8; 64.1; 61.5	0.7
SECONDARY Nasal Obstruction Symptom Evaluation (NOSE) Score Following Surgery in Subset of Patients Who Elect to Undergo Surgery.	70; 16.2; 17.6; 17.2; 22.2; 20	<0.001 sig

Summary

The purpose of this project is to determine if intranasal corticosteroids have an effect on nasal obstruction in patients with nasal septal deviation.

Eligibility Criteria

Inclusion Criteria

Age greater than 18
NOSE score greater than 55
Nasal septal deviation on exam

Exclusion Criteria

Intranasal steroid use within the last three months
Current systemic steroid use
Prior septal surgery
Individuals who are pregnant or actively breastfeeding

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02877485). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.